Selenium dioxide monohydrate

Oral

Selenium dioxide monohydrate deficiency

Adult: 100-500 mcg of Selenium dioxide monohydrate daily.

Intramuscular

Selenium dioxide monohydrate deficiency

Adult: 100-500 mcg of Selenium dioxide monohydrate daily.

Intravenous

Selenium dioxide monohydrate deficiency

Adult: 100-500 mcg of Selenium dioxide monohydrate daily.

Selenium dioxide monohydrate is mineral that is found in soil and occurs naturally in certain foods (such as whole grains, Brazil nuts, sunflower seeds, and seafood). Selenium dioxide monohydrate is not produced in the body, but it is needed for proper thyroid and immune system function.

Selenium dioxide monohydrate is used to treat or prevent Selenium dioxide monohydrate deficiency.

Selenium dioxide monohydrate has been used in alternative medicine as an aid to treat Hashimoto's thyroiditis (an autoimmune disorder of the thyroid), and to treat high cholesterol.

Not all uses for Selenium dioxide monohydrate have been approved by the FDA. Selenium dioxide monohydrate should not be used in place of medication prescribed for you by your doctor.

Selenium dioxide monohydrate may also be used for purposes not listed in this product guide.

Selenium dioxide monohydrate Injection provides 40 mcg Selenium dioxide monohydrate/mL. For metabolically stable adults receiving TPN, the suggested additive dosage level is 20 to 40 mcg Selenium dioxide monohydrate/day. For pediatric patients, the suggested additive dosage level is 3 mcg/kg/day.

In adults, Selenium dioxide monohydrate deficiency states resulting from long-term TPN support, Selenium dioxide monohydrate as selenomethionine or selenious acid, administered intravenously at 100 mcg/day for a period of 24 and 31 days, respectively, has been reported to reverse deficiency symptoms without toxicity.

Aseptic addition of Selenium dioxide monohydrate Injection to the TPN solution under laminar flow hood is recommended. Selenium dioxide monohydrate is physically compatible with the electrolytes and other trace elements usually present in amino-acid/dextrose solution used for TPN. Frequent monitoring of plasma Selenium dioxide monohydrate levels is suggested as a guideline for subsequent administration. The normal whole blood range for Selenium dioxide monohydrate is approximately 10 to 37 mcg/100 mL.

Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.

See also:
What is the most important information I should know about Selenium dioxide monohydrate?

Selenium dioxide monohydrate Injection should not be given undiluted by direct injection into a peripheral vein because of the potential for infusion phlebitis.

Use Selenium dioxide monohydrate as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Shake well before each use.
• Remove jewelry before using Selenium dioxide monohydrate.
• Do not use on broken or inflamed skin or scalp.
• To use Selenium dioxide monohydrate on the scalp - Massage 1 or 2 teaspoonfuls of the medicine on the wet scalp. Leave on the scalp for 2 to 3 minutes. Rinse scalp thoroughly. Wash hands well after treatment. If you are using Selenium dioxide monohydrate before or after bleaching, tinting, or permanent waving of hair, rinse hair for at least 5 minutes in cool running water.
• To use Selenium dioxide monohydrate on the skin - Apply a sufficient amount to cover affected areas of the body. Lather well with a small amount of water. Leave the medicine on the skin for 10 minutes. Rinse thoroughly in the shower. Wash hands well after treatment.
• If you miss a dose of Selenium dioxide monohydrate, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once

Ask your health care provider any questions you may have about how to use Selenium dioxide monohydrate.

Selenium dioxide monohydrate is used as a dietary supplement mainly in the treatment of Selenium dioxide monohydrate deficiency affecting young women and children with Keshan disease. It is also used for treatment of osteoarthiritis associated with poor Selenium dioxide monohydrate levels in body called Kashin-Beck Disease. Selenium dioxide monohydrate supplements are also used in patients with HIV/ AIDS to maintain the adequate Selenium dioxide monohydrate levels.

See also:
What other drugs will affect Selenium dioxide monohydrate?

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination

Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification

Dolutegravir: Selenium dioxide monohydrate may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral Selenium dioxide monohydrate. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral Selenium dioxide monohydrate. Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification

See also:
What are the possible side effects of Selenium dioxide monohydrate?

The amount of Selenium dioxide monohydrate present in Selenium dioxide monohydrate Injection is small. Symptoms of toxicity from Selenium dioxide monohydrate are unlikely to occur at the recommended dosage level.